Public Employees Retirement System of Ohio acquired a new stake in shares of DaVita Inc. (NYSE:DVA – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 9,185 shares of the company’s stock, valued at approximately $2,043,000.
Other hedge funds have also recently modified their holdings of the company. Capstone Investment Advisors LLC bought a new position in shares of DaVita during the second quarter worth $479,000. Redwood Investment Management LLC purchased a new stake in DaVita in the 2nd quarter worth $2,257,000. Transamerica Financial Advisors LLC bought a new position in shares of DaVita during the 2nd quarter valued at about $101,000. Corient Private Wealth LP purchased a new position in shares of DaVita during the second quarter valued at about $6,917,000. Finally, Bank of America Corp DE purchased a new position in shares of DaVita during the second quarter valued at about $145,057,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.
Insiders Place Their Bets
In other DaVita news, insider Kathleen Waters sold 15,405 shares of DaVita stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.90% of the company’s stock.
DaVita Trading Down 0.1%
DaVita (NYSE:DVA – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts forecast that DaVita Inc. will post 14.57 EPS for the current year.
Analysts Set New Price Targets
A number of equities research analysts recently commented on the company. Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $265.00 price objective on shares of DaVita in a report on Wednesday, August 5th. Barclays raised their target price on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Finally, Oppenheimer set a $220.00 price target on shares of DaVita in a research report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $221.75.
Get Our Latest Stock Report on DVA
About DaVita
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Read More
- Five stocks we like better than DaVita
- AI Token Costs Are Changing the Hardware vs. Software Debate
- 3 ETFs That Could Move as Rate Expectations Shift
- 3 Stocks With September Catalysts Investors Shouldn’t Ignore
- Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
